曲恩汀治疗肥厚型心肌病:一项2期试验
这项多中心、安慰剂对照2期试验将154例肥厚型心肌病患者随机分配至曲恩汀400mg每日两次或安慰剂治疗52周。
要点
- 曲恩汀400mg每日两次治疗52周可显著降低肥厚型患者左心室质量指数。
- 疗效部分通过减少心肌细胞质量介导,不良事件与安慰剂相似。
核心结论
- 在肥厚型心肌病患者中,曲恩汀治疗52周较安慰剂显著降低左心室质量指数。
研究设计与样本
- 多中心、安慰剂对照2期试验,纳入154例成人肥厚型心肌病患者,随机接受曲恩汀400mg每日两次或安慰剂治疗52周。
主要发现
- 曲恩汀的效应通过减少心肌细胞质量介导(平均因果中介效应-3.9 g/m2;95%CI -6.8至-0.9)。
- 两组不良事件发生率相似。
临床怎么用
- 对于左心室质量较高的肥厚型心肌病患者,曲恩汀可能作为降低左心室质量的潜在治疗选择,但需等待进一步研究确认临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Pathophysiological features of hypertrophic cardiomyopathy include left ventricular hypertrophy, myocardial fibrosis, and myocardial energy deficiency. Depletion of cardiomyocyte copper I ions leads to impaired mitochondrial function, a state associated with left ventricular hypertrophy. Unbound or loosely bound copper II ions activate profibrotic pathways. Trientine dihydrochloride improves intracellular copper I ion trafficking and availability, and chelates copper II ions. In preclinical studies, trientine improved myocardial mitochondrial function and reduced left ventricular hypertrophy and fibrosis. The efficacy and safety of trientine in persons with hypertrophic cardiomyopathy are unknown. METHODS: In this multicentre, placebo-controlled phase 2 trial, adults with hypertrophic cardiomyopathy, a left ventricular wall thickness of 15 mm or greater, and who were in New York Heart Association class I to III were randomly assigned to receive trientine 400 mg twice daily or placebo for 52 weeks. Patients with any left ventricular outflow tract (LVOT) gradient were eligible. The primary endpoint was the change in left ventricular mass indexed to body surface area measured using cardiovascular magnetic resonance. RESULTS: A total of 154 patients underwent randomization. The mean age was 53.4 years, median maximum left ventricular wall thickness was 20.0 mm, median maximum LVOT gradient was 6.0 mmHg, 18.6% of patients had a resting LVOT gradient ≥30 mmHg, and 61.7% were in New York Heart Association class I. At 52 weeks, the mean change in the left ventricular mass indexed to body surface area was -4.4 ± 7.7 g/m2 in the trientine group and -1.5 ± 6.1 g/m2 in the placebo group (between-group difference -3.2 g/m2; 95% confidence interval -5.6 to -0.8; P = .009). The efficacy of trientine increased at higher levels of baseline left ventricular mass (baseline left ventricular mass indexed to body surface area by treatment allocation interaction P = .015). The effect of trientine was mediated via a reduction in myocardial cellular mass (average causal mediated effect -3.9 g/m2; 95% confidence interval -6.8 to -0.9). The incidence of adverse events was similar in the two groups. CONCLUSIONS: Among patients with hypertrophic cardiomyopathy, treatment with trientine resulted in a significantly greater reduction in left ventricular mass indexed to body surface area than placebo. (Funded by NIHR; TEMPEST ClinicalTrials.gov number, NCT04706429).
引用
- Farrant JP, Dodd S, Rosala-Hallas A, et al. Trientine for hypertrophic cardiomyopathy: a phase 2 trial. Eur Heart J. 2026. PMID: 42455121. doi:10.1093/eurheartj/ehag512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。